Menu
Search
|

Menu

Close
X

Cytokinetics Inc CYTK.OQ (NASDAQ Stock Exchange Global Select Market)

8.90 USD
-- (--)
As of Jul 19
chart
Previous Close 8.90
Open --
Volume --
3m Avg Volume 104,751
Today’s High --
Today’s Low --
52 Week High 15.95
52 Week Low 6.80
Shares Outstanding (mil) 54.20
Market Capitalization (mil) 476.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
13
FY16
106
FY15
29
EPS (USD)
FY18
-0.560
FY17
-2.511
FY16
0.329
FY15
-0.966
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
32.93
8.16
Price to Book (MRQ)
vs sector
4.82
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
32.08
17.38
LT Debt to Equity (MRQ)
vs sector
32.08
13.24
Return on Investment (TTM)
vs sector
-56.26
13.13
Return on Equity (TTM)
vs sector
-135.61
15.07

EXECUTIVE LEADERSHIP

Leonard Patrick Gage
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Robert Blum
President, Chief Executive Officer, Director, Since 2007
Salary: $591,667.00
Bonus: $350,000.00
Ching Jaw
Chief Financial Officer, Senior Vice President, Since 2017
Salary: $212,884.00
Bonus: $125,000.00
Fady Malik
Executive Vice President - Research and Development, Since 2015
Salary: $447,866.00
Bonus: $170,884.00
David Cragg
Senior Vice President - Human Resources, Since 2009
Salary: $284,950.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

280 E Grand Ave
SOUTH SAN FRANCISCO   CA   94080-4808

Phone: +1650.6243000

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

SPONSORED STORIES